BioneXt LAB can now perform routine screening for circulating tumour DNA (ctDNA) released into the bloodstream when tumour cells die.
This technique, dubbed ‘liquid biopsy’, harnesses next-generation sequencing technology to screen plasma for mutated tumour DNA from carcinomas of the liver, stomach, pancreas, oesophagus, prostate gland, endometrium, head and neck region, kidneys, thyroid, and bladder—sometimes detecting tumours even before they are visible through medical imaging.
For more details, contact us by phone at 285 777 885 or e-mail at onconeXt@bionext.lu.